Patent ID: 7718620

Claim:
A method for treating or preventing ischemia-reperfusion injury of the kidney in a mammal, the method comprising administering to the mammal an effective amount of a peptide having the formula selected from the group consisting of: D-Arg-2′,6′-Dmt-Lys-Phe-NH 2 , D-Arg-2′,6′-Dmt-Phe-Lys-NH 2 , D-Arg-Phe-Lys-2′,6′-Dmt-NH 2 , D-Arg-Phe-2′,6′-Dmt-Lys-NH 2 , D-Arg-Lys-2′,6′-Dmt-Phe-NH 2 , D-Arg-Lys-Phe-2′,6′-Dmt-NH 2 , Phe-Lys-2′,6′-Dmt-D-Arg-NH 2 , Phe-Lys-D-Arg-2′,6′-Dmt-NH 2 , Phe-D-Arg-2′,6′-Dmt-Lys-NH 2 , Phe-D-Arg-Lys-2′,6′-Dmt-NH 2 , Phe-D-Arg-Phe-Lys-NH 2 , Phe-2′,6′-Dmt-D-Arg-Lys-NH 2 , Phe-2′,6′-Dmt-Lys-D-Arg-NH 2 , Dmp-D-Arg-Phe-Lys-NH 2 , Lys-Phe-2′,6′-Dmt-D-Arg-NH 2 , Lys-2′,6′-Dmt-D-Arg-Phe-NH 2 , Lys-2′,6′-Dmt-Phe-D-Arg-NH 2 , Lys-D-Arg-Phe-2′,6′-Dmt-NH 2 , Lys-D-Arg-2′,6′-Dmt-Phe-NH 2 , D-Arg-2′,6′-Dmt-D-Arg-Phe-NH 2 , D-Arg-2′,6′-Dmt-D-Arg-2′,6′-Dmt-NH 2 , D-Arg-2′,6′-Dmt-D-Arg-Tyr-NH 2 , D-Arg-2′,6′-Dmt-D-Arg-Trp-NH 2 , Trp-D-Arg-Phe-Lys-NH 2 , Trp-D-Arg-Tyr-Lys-NH 2 , Trp-D-Arg-Trp-Lys-NH 2 , Trp-D-Arg-Dmt-Lys-NH 2 , D-Arg-Trp-Lys-Phe-NH 2 , D-Arg-Trp-Phe-Lys-NH 2 , D-Arg-Trp-Lys-Dmt-NH 2 , D-Arg-Trp-Dmt-Lys-NH 2 , D-Arg-Lys-Trp-Phe-NH 2 , D-Arg-Lys-Trp-Dmt-NH 2 , Cyclohexyl-D-Arg-Phe-Lys-NH 2 , Ala-D-Arg-Phe-Lys-NH 2 , Lys-D-Arg-Tyr-NH 2 , Trp-D-Lys-Tyr-Arg-NH 2 , Phe-Arg-D-His-Asp, Met-Tyr-D-Lys-Phe-Arg (SEQ. ID. NO: 4), D-His-Glu-Lys-Tyr-D-Phe-Arg (SEQ. ID. NO: 5), Lys-D-Gln-Tyr-Arg-D-Phe-Trp-NH 2 (SEQ. ID. NO: 6), Phe-D-Arg-Lys-Trp-Tyr-D-Arg-His (SEQ. ID. NO: 7), Gly-D-Phe-Lys-Tyr-His-D-Arg-Tyr-NH 2 (SEQ. ID. NO: 8), Val-D-Lys-His-Tyr-D-Phe-Ser-Tyr-Arg-NH 2 (SEQ. ID. NO: 9), Trp-Lys-Phe-D-Asp-Arg-Tyr-D-His-Lys (SEQ. ID. NO: 10), Lys-Trp-D-Tyr-Arg-Asn-Phe-Tyr-D-His-NH 2 (SEQ. ID. NO: 11), Thr-Gly-Tyr-Arg-D-His-Phe-Trp-D-His-Lys (SEQ. ID. NO: 12), Asp-D-Trp-Lys-Tyr-D-His-Phe-Arg- D-Gly-Lys-NH 2 (SEQ. ID. NO: 13), D-His-Lys-Tyr-D-Phe-Glu-D-Asp-D-His-D-Lys-Arg-Trp-NH 2 (SEQ. ID. NO: 14), Ala-D-Phe-D-Arg-Tyr-Lys-D-Trp-His-D-Tyr-Gly-Phe (SEQ. ID. NO: 15), Phe-Phe-D-Tyr-Arg-Glu-Asp-D-Lys-Arg-D-Arg-His-Phe-NH 2 (SEQ. ID. NO: 17), Phe-Tyr-Lys-D-Arg-Trp-His-D-Lys-D-Lys-Glu-Arg-D-Tyr-Thr (SEQ. ID. NO: 18), Glu-Arg-D-Lys-Tyr-D-Val-Phe-D-His-Trp-Arg-D-Gly-Tyr-Arg-D-Met-NH 2 (SEQ. ID. NO: 20), Arg-D-Leu-D-Tyr-Phe-Lys-Glu-D-Lys-Arg-D-Trp-Lys-D-Phe-Tyr-D-Arg-Gly (SEQ. ID. NO: 21), D-Glu-Asp-Lys-D-Arg-D-His-Phe-Phe-D-Val-Tyr-Arg-Tyr-D-Tyr-Arg-His-Phe-NH 2 (SEQ. ID. NO: 22), Asp-Arg-D-Phe-Cys-Phe-D-Arg-D-Lys-Tyr-Arg-D-Tyr-Trp-D-His-Tyr-D-Phe-Lys-Phe (SEQ. ID. NO: 23), His-Tyr-D-Arg-Trp-Lys-Phe-D-Asp-Ala-Arg-Cys-D-Tyr-His-Phe-D-Lys-Tyr-His-Ser-NH 2 (SEQ. ID. NO: 24), Gly-Ala-Lys-Phe-D-Lys-Glu-Arg-Tyr-His-D-Arg-D-Arg-Asp-Tyr-Trp-D-His-Trp-His-D-Lys-Asp (SEQ. ID. NO: 25), and Thr-Tyr-Arg-D-Lys-Trp-Tyr-Glu-Asp-D-Lys-D-Arg-His-Phe-D-Tyr-Gly-Val-Ile-D-His-Arg-Tyr-Lys-NH 2 (SEQ. ID. NO: 26).